Mycenax Biotech Inc.
TWO: 4726.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Pei-Jiun Chen
- Employees
- 387
- Headquarters
- Zhubei, Taiwan
- IPO year
- 2012
- Market cap
- NT$5.9B
- Website
- https://www.mycenax.com.tw
Loading 4726…
Loading profile data…Frequently asked questions about 4726
What does Mycenax Biotech Inc. (4726.TWO) do?
Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes...
Where does 4726.TWO trade?
Mycenax Biotech Inc. (4726.TWO) trades on the Taipei Exchange.
What sector is 4726.TWO in?
Mycenax Biotech Inc. (4726.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Mycenax Biotech Inc.?
Pei-Jiun Chen is the chief executive officer of Mycenax Biotech Inc. (4726.TWO).
Where is Mycenax Biotech Inc. headquartered?
Mycenax Biotech Inc. is headquartered in Taiwan.
Does 4726.TWO pay a dividend?
Mycenax Biotech Inc. (4726.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4726.TWO go public?
Mycenax Biotech Inc. (4726.TWO) completed its initial public offering in 2012.